Gradientech presents QuickMIC® clinical study results
The diagnostics company Gradientech, developing QuickMIC® for ultra-rapid antibiotic susceptibility testing, today announces decisive results from the completed clinical performance evaluation study of QuickMIC and its gram-negative panel. The results exceed the regulatory requirements to achieve a CE-IVD registration.The clinical performance evaluation study of the QuickMIC system is completed with promising results to form the basis for a CE-IVD registration of QuickMIC following the IVD Directive. The study includes 473 bacterial strains of species common in sepsis, whereof 64 are